Back to Faculty
Faculty

Vivek Subbiah

MD
Jeffrey and Christina Bird Endowed Professor of Medicine
Stanford Cancer Institute

Vivek Subbiah, MD
Vivek Subbiah, MD, is a medical oncologist and early-phase clinical trialist with dual training in adult and pediatric oncology and 15+ years of leadership in oncology drug development. He holds the Jeffrey and Christina Bird Endowed Chair and is Professor of Medicine at Stanford University School of Medicine, Associate Director for Drug Development and Precision Oncology at Stanford Cancer Institute, and Executive Medical Director for Novel Therapies and the Clinical Trial Network at Stanford Health Care.
He has served as global Principal Investigator on trials contributing to 12+ FDA approvals across 15 cancer indications, including the tumor-agnostic approvals of dabrafenib/trametinib (ROAR) and selpercatinib and pralsetinib (LIBRETTO-001, ARROW). Across 150+ Phase I/II trials as principal investigator, his work spans targeted therapies, antibody-drug conjugates, immunotherapy, radioligand therapy, degraders, and cell therapies.
Previously held leadership positions at MD Anderson and Sarah Cannon Research Institute, he has published 450+ peer-reviewed articles and mentored 100+ early-career physician-scientists.

2026 Sessions

Plenary: Biomarkers Beyond Boundaries: Advancing Precision Oncology with Tumor-Agnostic Therapies

Tumor-agnostic therapies are reshaping precision oncology by enabling treatment decisions based on molecular alterations rather than tumor site. This plenary reviews key biomarkers, scientific rationale, and recent clinical advances driving this paradigm shift. The session examines the efficacy, safety, and mechanisms of approved and emerging tumor-agnostic agents, along with practical challenges such as testing access and interpretive complexity.

Presenter

Saturday, September 26 8:05–8:50 AM
Faculty

Vivek Subbiah

MD
Jeffrey and Christina Bird Endowed Professor of Medicine
Stanford Cancer Institute

Vivek Subbiah, MD
Vivek Subbiah, MD, is a medical oncologist and early-phase clinical trialist with dual training in adult and pediatric oncology and 15+ years of leadership in oncology drug development. He holds the Jeffrey and Christina Bird Endowed Chair and is Professor of Medicine at Stanford University School of Medicine, Associate Director for Drug Development and Precision Oncology at Stanford Cancer Institute, and Executive Medical Director for Novel Therapies and the Clinical Trial Network at Stanford Health Care.
He has served as global Principal Investigator on trials contributing to 12+ FDA approvals across 15 cancer indications, including the tumor-agnostic approvals of dabrafenib/trametinib (ROAR) and selpercatinib and pralsetinib (LIBRETTO-001, ARROW). Across 150+ Phase I/II trials as principal investigator, his work spans targeted therapies, antibody-drug conjugates, immunotherapy, radioligand therapy, degraders, and cell therapies.
Previously held leadership positions at MD Anderson and Sarah Cannon Research Institute, he has published 450+ peer-reviewed articles and mentored 100+ early-career physician-scientists.
Back to top